
Please try another search
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin’s lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company was founded in 1999 and is headquartered in Paris, France.
Name | Age | Since | Title |
---|---|---|---|
Dietger Niederwieser | - | 2017 | Member of Clinical Advisory Board |
Rainer J. Boehm | 64 | 2017 | Independent Director |
Andre Choulika | 60 | 1999 | Co-Founder, CEO & Director |
David J. Sourdive | 58 | 2000 | Co-Founder, Deputy CEO, Executive VP of CMC & Manufacturing and Director |
Ola Landgren | - | 2017 | Member of Clinical Advisory Board |
Stephan A. Grupp | - | 2018 | Member of Clinical Advisory Board |
Ghulam J. Mufti | - | - | Member of Clinical Advisory Board |
Jean-Pierre Garnier | 78 | 2020 | Independent Non-Executive Chairman |
Donald A. Bergstrom | 53 | 2021 | Independent Director |
Kanti Rai | - | 2017 | Member of Clinical Advisory Board |
Catherine Bollard | 57 | 2017 | Member of Clinical Advisory Board |
Marcela V. Maus | 49 | 2017 | Member of Clinical Advisory Board |
Laurent Arthaud | 62 | 2011 | Director |
Cecile Chartier | 57 | 2023 | Independent Director |
Tyrell Rivers | 52 | 2024 | Director |
Marc Dunoyer | 73 | 2024 | Director |
Andre C. Muller | 62 | 2025 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review